2.3. PRR-ligands, cytokines, neutralising antibodies, and inhibitors used in the stimulation experiments

The PRR-ligands used were: the lipopeptide Pam3CysSK4 [P3C] [TLR2/1] [300 ng/mL] [#L2000, EMC microcollections], Lipomannan [LM] [TLR2/6] [30 ng/mL] [#tlrl-hkmt-1], polyinosinic:polycytidylic acid (poly[I:C) [TLR3] [5–70 µg/mL] [#tlrl-pic], lipopolysaccharide [LPS] [TLR4] [100 ng/mL] [#tlrl-peklps], Flagellin [TLR5] [100 ng/mL] [#tlrl-stfla], the antiviral compound R848 [TLR7/8] [100 ng/mL] [#tlrl-r848], the peptidoglycan component muramyl dipeptide [MDP] [NOD2] [1 µg/mL] [#tlrl-mdp], all from InvivoGen, and unmethylated CpG dinucleotides [TLR9] [10 μM] [# 1712649, TibMolBiol].

Recombinant cytokines used were: IL-10 [100 ng/mL] [#200–10], IL-1β [100 ng/mL] [#200-01B], TNF [100–200 ng/mL] [#300-01A], and IFNβ [0.1–10 ng/ml] [#300-02BC] [all from PeproTech], IL12 [20 ng/mL] [#219-IL, R&D], and ISG15 [500 ng/ml] [#12729HNAE, Thermo Fisher Scientific]. JAK-inhibitors used were: filgotinib [10 µM] [GLPG0634] [#S7605, Selleckchem.com] and ruxolitinib [10 µM] [#tlrl-rux, InvivoGen]. Neutralising antibodies used were: rabbit anti-human IFN-β [2.5 µg/ml] [#500-P32B, PeproTech] and isotype control rabbit IgG [2.5 µg/ml] [#X0903, Dako Cytomation]. For details, see Supplementary Table 1, available as Supplementary data at ECCO-JCC online.